
Contineum Therapeutics, Inc. (NASDAQ:CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS).
RRMS is the most common type of MS, characterized by unpredictable periods of new or worsening symptoms (relapses) followed by periods of recovery (remissions).